Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$8.18 +2.8%	$6.62	$1.76 ▼ $8.72	$709.56M	-0.46	1.47 million shs	855,056 shs
AUTL Autolus Therapeutics	$2.37 -0.4%	$2.29	$1.11 ▼ $5.00	$633.42M	1.9	1.57 million shs	1.76 million shs
EPRX Eupraxia Pharmaceuticals	$5.36 -0.4%	$4.82	$2.20 ▼ $6.20	$193.46M	1.5	11,596 shs	2,644 shs
XNCR Xencor	$7.95	$8.69	$7.16 ▼ $27.24	$565.81M	0.89	604,991 shs	672,036 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	+2.76%	+2.89%	+29.84%	+68.49%	+315.23%
AUTL Autolus Therapeutics	-0.42%	-2.07%	0.00%	+93.47%	-44.24%
EPRX Eupraxia Pharmaceuticals	-0.09%	-3.94%	-1.92%	+41.42%	+104.58%
XNCR Xencor	0.00%	-9.86%	-5.41%	-0.50%	-55.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	2.9069 of 5 stars	4.5	1.0	0.0	1.3	2.5	0.6
AUTL Autolus Therapeutics	2.7501 of 5 stars	3.5	2.0	0.0	1.9	3.3	0.6
EPRX Eupraxia Pharmaceuticals	2.799 of 5 stars	3.6	2.0	0.0	3.3	0.0	0.6
XNCR Xencor	3.4822 of 5 stars	3.4	0.0	3.9	1.8	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$11.75	43.64% Upside
AUTL Autolus Therapeutics	3.00	Buy	$9.32	293.25% Upside
EPRX Eupraxia Pharmaceuticals	3.17	Buy	$11.00	105.22% Upside
XNCR Xencor	2.75	Moderate Buy	$28.00	252.20% Upside

Current Analyst Ratings Breakdown

Latest EPRX, AMLX, XNCR, and AUTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/24/2025	EPRX Eupraxia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$11.00
7/21/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/10/2025	AMLX Amylyx Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/24/2025	AMLX Amylyx Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$17.00
6/17/2025	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/16/2025	EPRX Eupraxia Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Speculative Buy
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	8.35	N/A	N/A	$2.40 per share	3.41
AUTL Autolus Therapeutics	$10.12M	62.33	N/A	N/A	$1.61 per share	1.47
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	$110.49M	5.12	N/A	N/A	$9.63 per share	0.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$301.74M	-$3.11	N/A	N/A	N/A	N/A	-77.21%	-63.84%	8/7/2025 (Confirmed)
AUTL Autolus Therapeutics	-$220.66M	-$0.88	N/A	N/A	N/A	N/A	-52.82%	-29.67%	8/12/2025 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$25.50M	-$0.76	N/A	N/A	N/A	N/A	-367.73%	-112.23%	8/6/2025 (Estimated)
XNCR Xencor	-$232.62M	-$3.06	N/A	N/A	N/A	-181.17%	-31.94%	-22.19%	N/A

Latest EPRX, AMLX, XNCR, and AUTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.2329	N/A	N/A	N/A	$12.92 million	N/A
8/7/2025	Q2 2025	AMLX Amylyx Pharmaceuticals	-$0.43	N/A	N/A	N/A	N/A	N/A
8/6/2025	N/A	EPRX Eupraxia Pharmaceuticals	-$0.21	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	AMLX Amylyx Pharmaceuticals	-$0.45	-$0.42	+$0.03	-$0.42	N/A	N/A
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million
5/8/2025	Q1 2025	XNCR Xencor	-$0.60	-$0.66	-$0.06	-$0.66	$23.44 million	$32.73 million
5/6/2025	Q1 2025	EPRX Eupraxia Pharmaceuticals	-$0.19	-$0.21	-$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.05	12.05
AUTL Autolus Therapeutics	N/A	9.24	9.02
EPRX Eupraxia Pharmaceuticals	N/A	11.10	11.10
XNCR Xencor	0.16	5.89	5.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
AUTL Autolus Therapeutics	72.83%
EPRX Eupraxia Pharmaceuticals	N/A
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	11.70%
AUTL Autolus Therapeutics	25.70%
EPRX Eupraxia Pharmaceuticals	N/A
XNCR Xencor	5.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.14 million	78.71 million	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
EPRX Eupraxia Pharmaceuticals	29	35.96 million	N/A	N/A
XNCR Xencor	280	71.17 million	67.45 million	Optionable

EPRX, AMLX, XNCR, and AUTL Headlines

Recent News About These Companies

Xencor (XNCR) to Release Earnings on Monday

August 3 at 2:17 AM | americanbankingnews.com

Short Interest in Xencor, Inc. (NASDAQ:XNCR) Rises By 127,291.3%

August 3 at 2:21 AM | americanbankingnews.com

Xencor, Inc. (NASDAQ:XNCR) Short Interest Update

August 2, 2025 | marketbeat.com

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

July 31, 2025 | finance.yahoo.com

Analysts Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $28.00

July 31, 2025 | americanbankingnews.com

Xencor (XNCR) Projected to Post Quarterly Earnings on Monday

July 28, 2025 | marketbeat.com

Y Intercept Hong Kong Ltd Invests $528,000 in Xencor, Inc. (NASDAQ:XNCR)

July 28, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of "Moderate Buy" by Brokerages

July 28, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Stock Price Down 4.3% - What's Next?

July 11, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Shares Pass Above 50 Day Moving Average - What's Next?

July 11, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Trading 7.3% Higher - What's Next?

July 9, 2025 | marketbeat.com

Xencor, Inc. (XNCR) Latest Stock News & Headlines - Yahoo Finance

June 29, 2025 | ca.finance.yahoo.com

Insider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,215 Shares of Stock

June 17, 2025 | insidertrades.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)

May 13, 2025 | theglobeandmail.com

Xencor Reports First Quarter 2025 Financial Results

May 7, 2025 | uk.finance.yahoo.com

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

May 7, 2025 | zacks.com

Xencor, Inc. (NASDAQ:XNCR) EVP Nancy Valente Sells 4,616 Shares

May 7, 2025 | insidertrades.com

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

May 1, 2025 | zacks.com

William Blair starts Xencor stock with Outperform rating

April 23, 2025 | uk.investing.com

William Blair Initiates Coverage of Xencor (XNCR) with Outperform Recommendation

April 22, 2025 | msn.com

Xencor initiated with an Outperform at William Blair

April 21, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX, AMLX, XNCR, and AUTL Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$8.18 +0.22 (+2.76%)

Closing price 08/5/2025 04:00 PM Eastern

Extended Trading

$9.99 +1.81 (+22.13%)

As of 04:00 AM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Autolus Therapeutics NASDAQ:AUTL

$2.37 -0.01 (-0.42%)

Closing price 08/5/2025 04:00 PM Eastern

Extended Trading

$2.39 +0.02 (+1.01%)

As of 04:11 AM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$5.36 -0.02 (-0.39%)

As of 08/5/2025 03:59 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Xencor NASDAQ:XNCR

$7.95 0.00 (0.00%)

Closing price 08/5/2025 04:00 PM Eastern

Extended Trading

$9.20 +1.25 (+15.72%)

As of 04:00 AM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time